Caris Life Sciences Inc. (CAI)
NASDAQ: CAI · Services-Medical Laboratories · Irving, TX
Our rating: Positive
Positive reaffirmed at $18.54, moderate conviction, November 19, 2026.
Breaks if: The Positive view breaks if reported revenue growth in the next full fiscal year prints below 20% year-over-year — which would indicate the near-doubling was a one-time reimbursement or adoption event rather than a durable inflection — or if free cash flow turns negative in any two consecutive reported quarters. A drawdown of 30% or more from $18.54 within the next 252 trading days would signal the market has fundamentally reassessed the growth story.
Key figures
| Market value | $5.0B |
|---|---|
| Revenue, last 12 months | $1.0B |
| Net income, last 12 months | $96M |
| Free cash flow, last 12 months | n/a |
| Price to earnings | 52.5× |
| Free cash flow yield | n/a |
| Dividend yield | 0.0% |
| Operating margin | 13.4% |
| Return on equity | 17.2% |
| Beta to the S&P 500 | 1.72 |
| Volatility, annualized | 68.0% |
Reported quarters
| Quarter ending | Revenue | Year on year | Earnings per share | Free cash flow |
|---|---|---|---|---|
| September 30, 2026 | $275M | 27.0% | $0.05 | −$40M |
| June 30, 2026 | $264M | 45.4% | $0.00 | n/a |
| March 31, 2026 | $216M | 78.8% | $0.00 | $23M |
| December 31, 2025 | $293M | 125.4% | $1.61 | $40M |
| September 30, 2025 | $217M | 113.4% | $0.08 | $55M |
| June 30, 2025 | $181M | 81.3% | $-7.97 | $6M |
| March 31, 2025 | $121M | n/a | $-3.57 | −$34M |
| December 31, 2024 | $130M | n/a | $-1.74 | −$41M |
Three-model forecasts for the next quarter
Written November 21, 2026, before the report. Each settles from the SEC filing.
- Revenue for the quarter is at least $0.50B: Claude 8%, Gemini 10%, Mistral 12%
- Diluted earnings per share are at least $1.61: Claude 12%, Gemini 10%, Mistral 8%
- Free cash flow for the quarter is at least $0.04B: Claude 38%, Gemini 35%, Mistral 38%
34 ledger entries and 2 corporate events on record. Share price as of November 20, 2026. Research and education only. Not investment advice. Stoquity does not manage money or know your circumstances. Ratings, forecasts and lists are produced by software and AI models and can be wrong. Performance figures are hypothetical, measured on paper against a benchmark, and say nothing certain about the future.